What is the recommended azithromycin dosing regimen for adults and children, including adjustments for renal or hepatic impairment and precautions for QT prolongation?

Azithromycin Dosing

For adults, azithromycin is typically dosed at 500 mg on day 1 followed by 250 mg daily on days 2-5 for most respiratory infections, or 500 mg daily for 3 days for acute bacterial exacerbations of COPD and acute bacterial sinusitis, with no dose adjustment required for renal or hepatic impairment. 1

Adult Dosing Regimens

Standard Respiratory Infections

• Community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin/skin structure infections: 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2-5 1
• Acute bacterial exacerbations of COPD: Either 500 mg daily for 3 days OR the 5-day regimen above 1
• Acute bacterial sinusitis: 500 mg daily for 3 days 1

Special Indications

• Genital ulcer disease (chancroid): Single 1 gram dose 1
• Non-gonococcal urethritis/cervicitis: Single 1 gram dose 1
• Gonococcal urethritis/cervicitis: Single 2 gram dose 1
• Babesiosis (in combination with atovaquone): 500-1000 mg on day 1, then 250 mg once daily thereafter for 7-10 days total; immunocompromised patients may require 600-1000 mg daily 2
• Lyme disease (erythema migrans, alternative agent): 500 mg daily for 7-10 days 2

Nontuberculous Mycobacterial Disease

For NTM pulmonary disease, azithromycin dosing differs significantly:

• Daily dosing: 250-500 mg per day 3
• Thrice weekly dosing: 500 mg per day 3

This lower-dose, chronic regimen is specific to mycobacterial infections and should not be confused with acute bacterial infection dosing.

Pediatric Dosing

Acute Otitis Media

Three regimens are available 1:

• 5-day regimen: 10 mg/kg on Day 1 (max 500 mg), then 5 mg/kg daily on Days 2-5 (max 250 mg/day)
• 3-day regimen: 10 mg/kg daily for 3 days (max 500 mg/day)
• Single-dose regimen: 30 mg/kg as a single dose (max 1500 mg)

Acute Bacterial Sinusitis

• 10 mg/kg once daily for 3 days (max 500 mg/day) 1

Community-Acquired Pneumonia

• 10 mg/kg on Day 1 (max 500 mg), then 5 mg/kg daily on Days 2-5 (max 250 mg/day) 1

Babesiosis (Pediatric)

• 10 mg/kg on day 1 (max 500 mg), then 5 mg/kg once daily thereafter (in combination with atovaquone) 2

Cholera (Pediatric)

• Azithromycin is recommended as first-choice for children with severe dehydration 4
• Single-dose treatment is particularly useful in epidemic situations 4

Renal Impairment

No dose adjustment is required for azithromycin in renal impairment, including patients on hemodialysis. 1, 5

The pharmacokinetic data supporting this recommendation is robust: in a study of 42 adults with varying degrees of renal impairment, mean Cmax and AUC increased only 5.1% and 4.2% respectively in mild-to-moderate renal impairment (GFR 10-80 mL/min) compared to normal renal function 1. Even in severe renal impairment (GFR <10 mL/min), the increases were 61% for Cmax and 35% for AUC—not sufficient to warrant dose reduction 1, 5.

Important caveat: Exercise caution in severe renal impairment (GFR <10 mL/min) due to the modest increase in exposure, though formal dose adjustment is not required 1.

Hepatic Impairment

No dose adjustment recommendations can be made for hepatic impairment because pharmacokinetic studies have not been performed in this population. 1

This represents a knowledge gap rather than evidence of safety. In the absence of data, clinical judgment is required when prescribing to patients with significant hepatic dysfunction.

QT Prolongation Precautions

Azithromycin carries a risk of QT prolongation and should be used with caution in patients with risk factors for cardiac arrhythmias. 6, 7, 8

Risk Stratification

Among macrolides, azithromycin has the lowest risk of QT prolongation compared to erythromycin (highest risk) and clarithromycin (intermediate risk) 6. However, it is still classified by CredibleMeds and the American Heart Association as a QT-prolonging drug known to cause Torsades de pointes 8.

Pre-Treatment Assessment

Before initiating azithromycin, particularly for chronic use:

• Obtain baseline ECG to assess QTc interval 7
• Contraindications: QTc >450 ms (men) or >470 ms (women) 7
• Screen for risk factors: history of heart disease, low potassium, slow pulse, family history of sudden death, prolonged QT interval 7
• Review concomitant medications for other QT-prolonging drugs (www.crediblemeds.org) 6, 7

Monitoring During Chronic Therapy

For patients on long-term azithromycin (e.g., for bronchiectasis or COPD):

• Repeat ECG 1 month after starting treatment 7
• If new QTc prolongation develops, stop treatment 7
• Monitor electrolytes and renal function, especially if taking diuretics 6

High-Risk Scenarios

Increased risk of Torsades de pointes occurs when:

• QTc exceeds 500 ms 6
• Drug increases QTc by >60-70 ms, particularly if rapidly 6
• Women (higher baseline risk) 6
• Elderly patients 6
• Underlying structural heart disease 6
• Concurrent use of multiple QT-prolonging medications 6, 7

Consider alternative antibiotics (penicillins, cephalosporins) when adding to existing QT-prolonging therapy rather than simply monitoring 6.

Drug Interactions

Azithromycin is a substrate of and inhibits P-glycoprotein and CYP2C9 (moderate), CYP2D6 (moderate), and CYP3A4 (weak) 9. While drug interactions are generally modest, be aware of potential interactions with drugs like warfarin (reduce dose by 50%), digoxin (reduce by 30-50%), and other substrates of these pathways 9.

Administration Considerations

• Can be taken with or without food 1
• Tablets and suspension are bioequivalent 1
• Extensive tissue distribution: Tissue concentrations exceed serum by up to 100-fold, with prolonged terminal half-life of 68 hours allowing for short treatment courses 1, 10
• Biliary excretion is the major route of elimination; only ~6% appears unchanged in urine 1

Common Pitfalls

1. Do not reduce dose in renal failure—this is a common error based on assumptions about antibiotic dosing 5
2. Do not assume hepatic dosing is safe—lack of data means caution is warranted, not reassurance 1
3. Do not ignore QT risk in "low-risk" patients—adolescent males with cystic fibrosis showed increased QTc after chronic azithromycin 11
4. Do not use macrolide monotherapy if NTM is identified—resistance concerns mandate combination therapy 7
5. For streptococcal pharyngitis in children, azithromycin results in more recurrence than penicillin and requires higher dosing (12 mg/kg/day for 5 days) 12